These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25474576)

  • 1. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
    Galabova G; Brunner S; Winsauer G; Juno C; Wanko B; Mairhofer A; Lührs P; Schneeberger A; von Bonin A; Mattner F; Schmidt W; Staffler G
    PLoS One; 2014; 9(12):e114469. PubMed ID: 25474576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.
    Momtazi-Borojeni AA; Jaafari MR; Badiee A; Sahebkar A
    Atherosclerosis; 2019 Apr; 283():69-78. PubMed ID: 30797988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement.
    Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW
    J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.
    Schroeder KM; Beyer TP; Hansen RJ; Han B; Pickard RT; Wroblewski VJ; Kowala MC; Eacho PI
    J Lipid Res; 2015 Nov; 56(11):2124-32. PubMed ID: 26392590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
    Seidah NG
    Curr Pharm Des; 2013; 19(17):3161-72. PubMed ID: 23317404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P
    Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.